Madrigal’s 2024 MASH drug sparks new wave of diagnosis and personalized treatment approaches

The article argues that the field of metabolic dysfunction‑associated steatohepatitis (MASH) is entering a period of rapid innovation, and that the industry must broaden efforts in diagnosis, monitoring and individualized therapy to reach more patients.

For many years MASH was considered one of the toughest targets for drug development, with few effective options despite large research investments. That changed in 2024 when Madrigal Pharmaceuticals secured the first regulatory approval for a MASH therapy.

The author notes that breakthrough medicines often reshape how diseases are identified and studied, creating new diagnostic tools, care pathways and clinical endpoints. This pattern has been seen in other areas such as cystic fibrosis and chronic myeloid leukemia.

Applying that experience to MASH, the piece calls on companies and researchers to expand the ecosystem around the approved drug, aiming to improve patient outcomes through more precise and earlier interventions.